41995-04-4

Basic information

• Product Name: Benzoyl chloride, 4-chloro-2-nitro-
• Synonyms: 2-nitro-4-chlorobenzoic acid chloride;Benzoyl chloride,4-chloro-2-nitro;4-chloro-2-nitrobenzoic acid chloride;4-Chlor-2-nitro-benzoylchlorid;4-chloro-2-nitro-benzoyl chloride;2-Nitro-4-chlorobenzoyl chloride
• CAS NO: 41995-04-4
• Molecular Formula: C7H3Cl2NO3
• Molecular Weight: 220.012
• Mol File: 41995-04-4.mol
• Article Data: 29

Chemical Properties

• CAS DataBase Reference: Benzoyl chloride, 4-chloro-2-nitro-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoyl chloride, 4-chloro-2-nitro-(41995-04-4)
• EPA Substance Registry System: Benzoyl chloride, 4-chloro-2-nitro-(41995-04-4)

Safety Data

• Hazardous Substances Data: 41995-04-4(Hazardous Substances Data)

Upstream product

• 89-63-4 4-Chloro-2-nitroaniline 
• 34662-32-3 4-chloro-2-nitrobenzonitrile 
• 89-59-8 4-chloro-2-nitrotoluene 
• 6280-88-2 4-chloro-2-nitro-benzoic acid 

Downstream Products

• 859962-09-7 (4-chloro-2-nitro-phenyl)-[2]furyl ketone 
• 144485-98-3 4-Chloro-N-(3-methyl-isoxazol-5-yl)-2-nitro-benzamide 
• 41994-91-6 4-chloro-2-nitrobenzoic amide 
• 945920-67-2 α,α-dideuterio-4-chloro-2-nitrobenzyl alcohol 
• 349139-57-7 4-chloro-N-[2-(4-methoxy-phenyl)-ethyl]-2-nitro-benzamide 
• 115582-02-0 4-(2'-Nitro-4'-chlorobenzoyl)-2,2-dimethyl-2H-pyran-3,5-(4H,6H)-dione 
• 69558-89-0 1-(4-chloro-2-nitro-benzoyl)-4-methyl-piperazine 
• 93215-00-0 8-(2-amino-4-chlorophenyl)-3,9-dihydro-1,3-bis(2-propenyl)-1H-purine-2,6-dione 

Relevant articles and documents

AROMATIC DERIVATIVE, PREPARATION METHOD FOR SAME, AND MEDICAL APPLICATIONS THEREOF

The present invention relates to an aromatic derivative, a preparation method thereof and medical applications thereof. Particularly, the present invention relates to a novel compound as shown in the general formula (I) and a pharmaceutically acceptable s

INHIBITORS OF KRAS G12C

Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, tautomer, prodrug or stereoisomer thereof, wherein R1, R2a, R3a, R3b, R4a, R4b, G1, G2, L1, L2, m1, m2, A, B, W, X, Y, Z and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.

Synthesis and Quantitative Structure-Activity Relationships of Selective BCRP Inhibitors

The breast cancer resistance protein (BCRP/ABCG2) is a member of the ABC transporter superfamily. This protein has a number of physiological functions, including protection of the human body from xenobiotics. The overexpression of BCRP in certain tumor cell lines causes cross-resistance against various drugs used in chemotherapeutic treatment. In a previous work we showed that a new class of compounds derived from XR9576 (tariquidar) selectively inhibits BCRP. In this work we synthesized more members of this class, with modification on the second and third aromatic rings. The inhibitory activities against BCRP and P-gp were assayed using a Hoechst 33342 assay for BCRP and a calcein AM assay for P-gp. Finally, quantitative structure-activity relationships for both aromatic rings were established. The results obtained show the importance of the electron density on the third aromatic ring, influenced by substituents, pointing to interactions with aromatic residues of the protein binding site. In the second aromatic ring the activity of compounds is influenced by the steric volume of the substituents.